CN114831954A - 一种左氧氟沙星片 - Google Patents
一种左氧氟沙星片 Download PDFInfo
- Publication number
- CN114831954A CN114831954A CN202210335384.7A CN202210335384A CN114831954A CN 114831954 A CN114831954 A CN 114831954A CN 202210335384 A CN202210335384 A CN 202210335384A CN 114831954 A CN114831954 A CN 114831954A
- Authority
- CN
- China
- Prior art keywords
- levofloxacin
- tablet
- coating
- release
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 title claims abstract description 37
- 229960003376 levofloxacin Drugs 0.000 title claims abstract description 37
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 28
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 23
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 17
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 17
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 17
- 239000008101 lactose Substances 0.000 claims abstract description 17
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims abstract description 16
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 8
- 239000001087 glyceryl triacetate Substances 0.000 claims abstract description 8
- 235000013773 glyceryl triacetate Nutrition 0.000 claims abstract description 8
- 229960002622 triacetin Drugs 0.000 claims abstract description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims description 35
- 239000003826 tablet Substances 0.000 claims description 34
- 239000011248 coating agent Substances 0.000 claims description 32
- 239000007939 sustained release tablet Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 229960003943 hypromellose Drugs 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 230000004584 weight gain Effects 0.000 claims description 4
- 235000019786 weight gain Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 abstract description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000012792 core layer Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960001699 ofloxacin Drugs 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008029 phthalate plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210312756 | 2022-03-28 | ||
CN2022103127564 | 2022-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114831954A true CN114831954A (zh) | 2022-08-02 |
Family
ID=82563581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210335384.7A Pending CN114831954A (zh) | 2022-03-28 | 2022-03-31 | 一种左氧氟沙星片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114831954A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101756926A (zh) * | 2008-12-23 | 2010-06-30 | 北京科信必成医药科技发展有限公司 | 一种氧氟沙星缓释片及其制备方法 |
US20140341993A1 (en) * | 2011-12-26 | 2014-11-20 | Ems S.A. | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof |
-
2022
- 2022-03-31 CN CN202210335384.7A patent/CN114831954A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101756926A (zh) * | 2008-12-23 | 2010-06-30 | 北京科信必成医药科技发展有限公司 | 一种氧氟沙星缓释片及其制备方法 |
US20140341993A1 (en) * | 2011-12-26 | 2014-11-20 | Ems S.A. | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof |
Non-Patent Citations (1)
Title |
---|
裴志强;尹莉芳;周建平;: "中心复合设计法优化盐酸左氧氟沙星缓释片处方" * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2540465C2 (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
JP5401327B2 (ja) | 溶出性の改善された錠剤 | |
HU226595B1 (en) | Modified release multiple-units dosage composition | |
TWI795462B (zh) | 光安定性及溶出性優異的醫藥製劑 | |
EP2921170A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
NZ201008A (en) | Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient | |
JP2007503414A (ja) | 新規なロピニロール処方 | |
AU2005309297A1 (en) | Novel formulation of pyridoxal 5'-phosphate and method of preparation | |
JP7293131B2 (ja) | 新規微粒子コーティング(薬物含有中空粒子及びその製法) | |
AU2014224238B2 (en) | Formulations of organic compounds | |
US20150283248A1 (en) | Pharmaceutical compositions of Linagliptin and process for preparation thereof | |
EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
CN103816135B (zh) | 盐酸美金刚缓释制剂及其制备方法 | |
CN109966269A (zh) | 一种盐酸美金刚缓释微丸制剂及其制备方法 | |
WO2005044238A1 (en) | Modified release solid dosage form of amphetamine salts | |
CN101596162B (zh) | 盐酸多西环素肠溶微丸 | |
CN114831954A (zh) | 一种左氧氟沙星片 | |
EP2726063A1 (en) | Ibuprofen chewable tablet | |
JP2021526506A (ja) | 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤 | |
KR101618373B1 (ko) | 경구 투여가 가능한 항피로에 효과를 나타내는 새로운 복합비타민 제제 | |
CN110101687B (zh) | 一种盐酸二甲双胍缓释制剂及其制备方法 | |
US20100310652A1 (en) | Coated extended release pharmaceutical compositions of levetiracetam | |
US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
KR101761983B1 (ko) | 구강내 속붕해 필름 조성물 및 그 제조방법 | |
CN114340601A (zh) | 掩盖了令人不快的味道的颗粒剂及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240119 Address after: 571127 Guilin Ocean Economic Development Zone, Meilan District, Haikou City, Hainan Province Applicant after: HAINAN POLY PHARM. Co.,Ltd. Applicant after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Address before: 311100 No.78 Xinzhou Road, Yuhang Economic Development Zone, Yuhang District, Hangzhou City, Zhejiang Province Applicant before: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Applicant before: HAINAN POLY PHARM. Co.,Ltd. Applicant before: Anhui Puli Pharmaceutical Co.,Ltd. |
|
TA01 | Transfer of patent application right |